Mary G Stack

US Patent:

7595047, Sep 29, 2009

Filed:

Apr 13, 2006

Appl. No.:

11/403607

Inventors:

Tammy L. Moser - Durham NC, US
Salvatore V. Pizzo - Bahama NC, US
Mary S. Stack - Chicago IL, US

Assignee:

Duke University - Durham NC
Northwestern University - Evanston IL

International Classification:

A61K 39/395
C07K 16/00

US Classification:

4241411, 4241381, 4241551, 4241301, 4241331, 5303871, 5303873, 5303877, 5303881

Abstract:

Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies.

US Patent:

8048415, Nov 1, 2011

Filed:

Aug 11, 2009

Appl. No.:

12/538952

Inventors:

Tammy L. Moser - Durham NC, US
Salvatore V. Pizzo - Bahama NC, US
Mary S. Stack - Chicago IL, US

Assignee:

Duke University - Durham NC
Northwestern University - Evanston IL

International Classification:

A61K 39/395
A61K 39/00
C07K 16/28
C12P 21/08

US Classification:

4241301, 4241331, 4241381, 4241411, 4241431, 5303871, 5303873, 5303881, 53038822

Abstract:

Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase, particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies.

US Patent:

20030017512, Jan 23, 2003

Filed:

Dec 10, 2001

Appl. No.:

10/007698

Inventors:

Tammy Moser - Durham NC, US
Salvatore Pizzo - Bahama NC, US
Mary Stack - Chicago IL, US

International Classification:

G01N033/574

US Classification:

435/007230

Abstract:

The present invention relates, in general, to an angiostatin receptor and, in particular, to an angiostatin receptor present on cellular plasma membranes. More particularly, the present invention relates to the human angiostatin receptor, ATP synthase, or subunit or portion thereof, and to the use thereof in assays designed to screen compounds for their ability to serve as agonists or antagonists of human angiostatin. The invention further relates to nucleic acid sequences encoding ATP synthase, or subunit or portion thereof, and to host cells transformed therewith. The invention also relates to antibodies specific for ATP synthase.

US Patent:

20040022788, Feb 5, 2004

Filed:

May 22, 2001

Appl. No.:

09/862798

Inventors:

Tammy Moser - Durham NC, US
Salvatore Pizzo - Bahama NC, US
Mary Stack - Chicago IL, US

International Classification:

A61K048/00
A61K039/395
A61K038/43
A61K009/127

US Classification:

424/146100, 424/450000, 514/012000, 514/044000, 424/094100

Abstract:

Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase, particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies. The compounds can be conjugated to or combined with various cytotoxic agents and/or labeled compounds. Methods for promoting angiogenesis can be used to introduce vasculature to areas in a patient that can benefit from such increased vasculature. Methods for inhibiting angiogenesis can be used to treat disorders mediated by angiogenesis, for example, tumors, autoimmune disorders such as rheumatoid arthritis, and the like.

US Patent:

6444431, Sep 3, 2002

Filed:

May 19, 1999

Appl. No.:

09/314159

Inventors:

Tammy L. Moser - Durham NC
Salvatore V. Pizzo - Bahama NC
Mary S. Stack - Chicago IL

Assignee:

Duke University - Durham NC
Northwestern University - Evanston IL

International Classification:

G01N 3353

US Classification:

435 72, 435 4, 435 71, 435 723, 530350, 5303871

Abstract:

The present invention relates, in general, to an angiostatin receptor and, in particular, to an angiostatin receptor present on cellular plasma membranes. More particularly, the present invention relates to the human angiostatin receptor, ATP synthase, or subunit or portion thereof, and to the use thereof in assays designed to screen compounds for their ability to serve as agonists or antagonists of human angiostatin. The invention further relates to nucleic acid sequences encoding ATP synthase, or subunit or portion thereof, and to host cells transformed therewith. The invention also relates to antibodies specific for ATP synthase.